The Pharma is a global pharmaceutical company headquartered in Japan and is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets.
In addition to a strong portfolio of medicines for hypertension and thrombotic disorders, under the Group’s 2025 Vision, the Pharma Research and Development is primarily focused on bringing forth novel therapies in oncology, including immuno-oncology, with additional focus on new horizon areas, such as pain management, neurodegenerative diseases, heart and kidney conditions, and rare diseases. The Pharma is currently looking for partnering and in-licensing opportunities across the globe.
The Pharma is currently looking for innovative therapeutics targeting the following priority areas: oncology, pain management, cardiovascular disease, CNS, and rare diseases. Other interest areas include novel therapeutic targets and approaches for the gut microbiome that can modulate disease outcome, cell therapeutics for serious diseases including Stroke/TIA, PAD/CLI and hepatic cirrhosis, and novel therapies for hematological diseases, especially for anemic disorders with erythropoietin resistance. The Pharma is open to biologics or small molecules, with an increased interest in new platform technologies. The following areas are currently out of focus: diabetes, hypertension, dyslipidemia, psychiatric diseases, and immunodeficiency.
The Pharma partners with privately held life science companies with experienced management teams and innovative technologies in the abovementioned areas.
If you are interested in more information about this investor and other investors tracked by LSN, please email RESI@lifesciencenation.com.
Next Phase Newsletter 
Leave a Reply